Shield Therapeutics plc announced the appointment of Fabiana Lacerca-Allen and Anders Lundstrom, as Independent Non-Executive Directors of the Company with immediate effect. Mrs. Lacerca-Allen is currently Senior Vice President, Chief Compliance Officer at Aimmune Therapeutics based in San Francisco, California (a Nestlé Health Science Corporation since October 2020). She brings to Shield extensive experience in compliance having started and implemented compliance programmes at several major pharmaceutical companies including Merck, Sharp & Dohme, Bristol-Myers Squibb Company, Mylan Laboratories and Elan Pharmaceuticals. Mrs. Lacerca-Allen was also a non-executive director at ArthroCare Corporation, a publicly traded company in the medical device sector prior to its acquisition by Smith & Nephew in 2014. Mrs. Lacerca-Allen will become a member of the Group's Audit Committee. Mr. Lundstrom is currently Executive Vice President and Chief Commercial Officer at Banner Life Sciences where he is planning and executing a US launch of a novel fumerate, Bafiertam, for the treatment of Multiple Sclerosis. He has over 25 years' experience in the pharmaceutical industry and has held senior commercial roles in AstraZeneca, Biogen, Orexo AB, where he was President and CEO from 2011 to 2013, and EMD Serono. Mr. Lundstrom will join the Remuneration Committee, replacing Rolf Hoffmann who, as previously announced, is not seeking re-election at the next Annual General Meeting.